Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01285609
Other study ID # CA184-104
Secondary ID 2009-017396-19
Status Completed
Phase Phase 3
First received
Last updated
Start date January 16, 2011
Est. completion date August 22, 2017

Study information

Verified date June 2020
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.


Description:

The primary objective is to compare Overall Survival (OS) of participants with Stage IV/recurrent NSCLC of squamous histology who have been randomized to ipilimumab in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel and carboplatin, and have received at least one dose of blinded study therapy (ipilimumab or placebo).


Recruitment information / eligibility

Status Completed
Enrollment 1289
Est. completion date August 22, 2017
Est. primary completion date June 9, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

- Non small cell lung cancer (NSCLC) - squamous cell

- Stage IV or recurrent NSCLC

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

- Brain Metastases

- Autoimmune diseases

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ipilimumab

Placebo

Paclitaxel

Carboplatin


Locations

Country Name City State
Argentina Local Institution Cordoba
Argentina Local Institution Cordoba
Argentina Local Institution Mendoza
Argentina Local Institution Quilmes Buenos Aires
Argentina Local Institution Rosario Santa FE
Argentina Local Institution San Miguel De Tucuman Tucuman
Argentina Local Institution Santa Fe
Australia Local Institution Bedford Park South Australia
Australia Local Institution Box Hill Victoria
Australia Local Institution Frankston Victoria
Australia Local Institution Heidelberg Victoria
Australia Local Institution Wodonga Victoria
Austria Local Institution Graz
Austria Local Institution Linz
Austria Local Institution Salzburg
Belgium Local Institution Aalst
Belgium Local Institution Liege
Belgium Local Institution Sint Niklaas
Belgium Local Institution Yvoir
Brazil Local Institution Barretos SAO Paulo
Brazil Local Institution Belo Horizonte Minas Gerais
Brazil Local Institution Curitiba Parana
Brazil Local Institution Fortaleza Ceara
Brazil Local Institution Passo Fundo RIO Grande DO SUL
Brazil Local Institution Porto Alegre
Brazil Local Institution Ribeirao Preto
Brazil Local Institution Rio de Janeiro
Brazil Local Institution Sao Jose dos Campos SAO Paulo
Brazil Local Institution Sao Paulo
Brazil Local Institution Sao Paulo
Canada Local Institution Montreal Quebec
Canada Local Institution Montreal Quebec
Canada Local Institution Montreal Quebec
Canada Local Institution Oshawa
Chile Local Institution Santiago Metropolitana
Chile Local Institution Santiago Metropolitana
Chile Local Institution Vina Del Mar Valparaiso
China Local Institution Beijing
China Local Institution Beijing
China Local Institution Beijing
China Local Institution Beijing
China Local Institution Changchun Jilin
China Local Institution Guangzhou Guangdong
China Local Institution Guanzhou Guangdong
China Local Institution Hangzhou Zhejiang
China Local Institution Nanjing Jiangsu
China Local Institution Nanjing Jiangsu
China Local Institution Santiago
China Local Institution Shanghai
China Local Institution Shanghai
China Local Institution Shantou Guangdong
China Local Institution Suzhou Jiangsu
China Local Institution Urumqi Xinjiang
China Local Institution Wuhan Hubei
China Local Institution Xi'an Shaanxi
China Local Institution Xi'an Shaanxi
Colombia Local Institution Monteria Cordoba
Colombia Local Institution Pereira Risaralda
Czechia Local Institution Ostrava Poruba
Czechia Local Institution Prague 2
Czechia Local Institution Praha 5
Czechia Local Institution Praha 8
Czechia Local Institution Pribram V-Zdabor
Czechia Local Institution Usti Nad Labem
Czechia Local Institution Znojmo
Denmark Local Institution Aalborg
Denmark Local Institution Herlev
Denmark Local Institution Hillerod
Denmark Local Institution Naestved
Denmark Local Institution Odense
France Local Institution Caen Cedex 05
France Local Institution Marseille Cedex 20
France Local Institution Paris
France Local Institution Poitiers
France Local Institution Rennes Cedex 9
France Local Institution Toulouse Cedex 9
France Local Institution Vandoeuvre-les-nancy
Germany Local Institution Bad Berka
Germany Local Institution Bochum
Germany Local Institution Darmstadt
Germany Local Institution Dresden
Germany Local Institution Frankfurt Am Main
Germany Local Institution Gauting
Germany Local Institution Grosshandsdorf
Germany Local Institution Hamburg
Germany Local Institution Heidelberg
Germany Local Institution Kassel
Germany Local Institution Lubeck
Germany Local Institution Mainz
Germany Local Institution Muenchen
Germany Local Institution Neumunster
Germany Local Institution Nuernberg
Germany Local Institution Regensburg
Germany Local Institution Tuebingen
Germany Local Institution Ulm
Germany Local Institution Villingen-Schwenningen
Hong Kong Local Institution Hong Kong
Hong Kong Local Institution Hong Kong
Hong Kong Local Institution New Territories
Hungary Local Institution Budapest
Hungary Local Institution Budapest
Hungary Local Institution Deszk
Hungary Local Institution Farkasgyepu
Hungary Local Institution Gyula
Hungary Local Institution Matrahaza
Hungary Local Institution Nyiregyhaza
Hungary Local Institution Pecs
Hungary Local Institution Sopron
Hungary Local Institution Szekesfehervar
Hungary Local Institution Szolnok
Ireland Local Institution Dublin
Ireland Local Institution Dublin
Ireland Local Institution Dublin
Ireland Local Institution Galway
Israel Local Institution Beer Sheva
Israel Local Institution Haifa
Israel Local Institution Jerusalem
Israel Local Institution Nahariya
Israel Local Institution Petah-Tikva
Israel Local Institution Rehovot
Israel Local Institution Tel Aviv
Israel Local Institution Tel-aviv
Israel Local Institution Tel-hashomer
Israel Local Institution Zerifin
Italy Local Institution Benevento
Italy Local Institution Bologna
Italy Local Institution Lido Di Camaiore
Italy Local Institution Lucca
Italy Local Institution Monza
Italy Local Institution Padova
Italy Local Institution Perugia
Italy Local Institution Siena
Italy Local Institution Sondrio
Italy Local Institution Terni
Italy Local Institution Treviglio
Japan Local Institution Akashi, Hyogo
Japan Local Institution Chuo-ku Tokyo
Japan Local Institution Fukuoka
Japan Local Institution Hirakata-shi Osaka
Japan Local Institution Kanazawa-shi Ishikawa
Japan Local Institution Kashiwa Chiba
Japan Local Institution Kurashiki-shi Okayama
Japan Local Institution Kurashiki-shi Okayama
Japan Local Institution Matsuyama, Ehime
Japan Local Institution Nagoya Aichi
Japan Local Institution Nagoya-shi Aichi
Japan Local Institution Natori-shi Miyagi
Japan Local Institution Osaka-shi Osaka
Japan Local Institution Osakasayama-city
Japan Local Institution Sapporo Hokkaido
Japan Local Institution Sapporo, Hokkaido
Japan Local Institution Sendai Miyagi
Japan Local Institution Sendai, Miyagi
Japan Local Institution Sunto-gun Shizuoka
Japan Local Institution Takatsuki
Japan Local Institution Tokyo
Japan Local Institution Ube-shi Yamaguchi
Japan Local Institution Yokohama-Shi Kanagawa
Japan Local Institution Yokohama-shi Kanagawa
Korea, Republic of Local Institution Busan
Korea, Republic of Local Institution Cheonju-si Chungcheongbuk-do
Korea, Republic of Local Institution Daegu
Korea, Republic of Local Institution Goyang-si Gyeonggi-do
Korea, Republic of Local Institution Gyeonggi-do
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution Seoul
Korea, Republic of Local Institution Seoul Kangnam-gu
Korea, Republic of Local Institution Seoul Seodaemungu
Korea, Republic of Local Institution Suwon
Korea, Republic of Local Institution Suwon-si Gyeonggi-do
Mexico Local Institution Mexico Distrito Federal
Mexico Local Institution Monterrey Nuevo LEON
Mexico Local Institution Zapopan Jalisco
Netherlands Local Institution Breda
Netherlands Local Institution Harderwijk
Netherlands Local Institution Hertogenbosch
Netherlands Local Institution Nieuwegein
Peru Local Institution Arequipa
Peru Local Institution Cercado
Peru Local Institution Lima
Peru Local Institution Trujillo LA Libertad
Poland Local Institution Elblag
Poland Local Institution Gdansk
Poland Local Institution Gdansk- Zaspa
Poland Local Institution Grudziadz
Poland Local Institution Olsztyn
Poland Local Institution Otwock
Poland Local Institution Poznan
Poland Local Institution Szczecin
Poland Local Institution Torun
Poland Local Institution Warsaw
Portugal Local Institution Lisboa
Portugal Local Institution Lisboa
Portugal Local Institution Porto
Portugal Local Institution Santa Maria Da Feira
Portugal Local Institution Sao Martinho Do Bispo Coimbra
Portugal Local Institution Vila Nova De Gaia
Romania Local Institution Bucharest
Romania Local Institution Bucuresti
Romania Local Institution Cluj Napoca
Romania Local Institution Sibiu
Romania Local Institution Suceava
Romania Local Institution Timisoara
Russian Federation Local Institution Chelyabinsk
Russian Federation Local Institution Kazan
Russian Federation Local Institution Moscow
Russian Federation Local Institution Moscow
Russian Federation Local Institution Pyatigorsk
Russian Federation Local Institution Saint Petersburg
Russian Federation Local Institution St-Peterburg
Russian Federation Local Institution St. Petersburg
Russian Federation Local Institution Tula
Singapore Local Institution Singapore
South Africa Local Institution Cape Town
South Africa Local Institution Durban
South Africa Local Institution Panorama,cape Town Western CAPE
South Africa Local Institution Vereeniging Gauteng
Spain Local Institution Avila
Spain Local Institution Barakaldo Vizcaya
Spain Local Institution Benidorm-alicante
Spain Local Institution Castellon
Spain Local Institution Madrid
Spain Local Institution Madrid
Spain Local Institution Manresa
Spain Local Institution Ourense
Spain Local Institution Valencia
Spain Local Institution Valencia
Sweden Local Institution Gothenburg
Sweden Local Institution Lund
Sweden Local Institution Stockholm
Sweden Local Institution Umea
Switzerland Local Institution Basel
Switzerland Local Institution Winterthur
Taiwan Local Institution Changhua City
Taiwan Local Institution Chiayi
Taiwan Local Institution Kaohsiung County
Taiwan Local Institution Taichung
Taiwan Local Institution Taichung
Taiwan Local Institution Taipei
Taiwan Local Institution Taipei
Taiwan Local Institution Taipei City
Thailand Local Institution Bangkok Tungpayathai
Thailand Local Institution Bangkok
Thailand Local Institution Bangkok
Thailand Local Institution Bangkok
Thailand Local Institution Chiang Mai
Thailand Local Institution Songkhla
United Kingdom Local Institution Dundee Angus/forfarshire
United Kingdom Local Institution Nottingham
United Kingdom Local Institution Sheffield
United Kingdom Local Institution Southampton Hampshire
United Kingdom Local Institution Truro Cornwall
United States Texas Oncology, PA - South Austin Cancer Center Austin Texas
United States Blue Ridge Cancer Care Blacksburg Virginia
United States Lynn Cancer Institute Center For Hematology-Oncology Boca Raton Florida
United States Gabrail Cancer Center Research Canton Ohio
United States Associated in Oncology and Hematology Chattanooga Tennessee
United States University Of Illinois At Chicago Medical Center Chicago Illinois
United States Wjb Dorn Va Medical Center Columbia South Carolina
United States Durham Va Medical Center (111g) Durham North Carolina
United States Cancer Center Of The Carolinas Greenville South Carolina
United States Kentucky Cancer Clinic Hazard Kentucky
United States Carolina Biooncology Institute Huntersville North Carolina
United States St. Francis Hospital & Health Centers Indianapolis Indiana
United States Integrated Community Oncology Network Jacksonville Florida
United States University Of Kansas Cancer Center Kansas City Missouri
United States Tennessee Cancer Specialists Knoxville Tennessee
United States Thompson Oncology Group Knoxville Tennessee
United States Clinical Research Alliance, Inc. Lake Success New York
United States Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
United States Novant Health Oncology Specialists Lexington North Carolina
United States Norton Cancer Institute Louisville Kentucky
United States Wisconsin Institutes for Medical Research Madison Wisconsin
United States Montgomery Cancer Center Mount Sterling Kentucky
United States Floyd Memorial Cancer Center Of Indiana New Albany Indiana
United States Kaiser Permanente Northwest Region Portland Oregon
United States Quincy Medical Group Quincy Illinois
United States Washington University School Of Medicine Saint Louis Missouri
United States Sharp Memorial Hospital San Diego California
United States Guthrie Medical Group, P.C. Sayre Pennsylvania
United States Presence Medical Group Hematology Oncology Skokie Illinois
United States Southern Illinois University School Of Medicine Springfield Illinois
United States Oklahoma Oncology And Hematology, Pc Dba Tulsa Oklahoma
United States Va Connecticut Healthcare System West Haven Connecticut
United States St Joseph Mercy Hospital Ypsilanti Michigan

Sponsors (1)

Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Canada,  Chile,  China,  Colombia,  Czechia,  Denmark,  France,  Germany,  Hong Kong,  Hungary,  Ireland,  Israel,  Italy,  Japan,  Korea, Republic of,  Mexico,  Netherlands,  Peru,  Poland,  Portugal,  Romania,  Russian Federation,  Singapore,  South Africa,  Spain,  Sweden,  Switzerland,  Taiwan,  Thailand,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint Overall Survival (OS) was defined as the time from randomization to the date of death. Participants that had not died were censored at last known date alive. Median OS time was calculated using Kaplan-Meier Estimates. Analysis for the Primary Endpoint occurred when the following 2 conditions were both met: (1) 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and (2) 705 deaths were observed in all randomized participants. Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)
Secondary Overall Survival (OS) in All Randomized Participants at Primary Endpoint Overall Survival (OS) was defined as the time from randomization to the date of death. Participants that had not died were censored at last known date alive. Median OS time was calculated using Kaplan-Meier Estimates. Analysis for the Primary Endpoint occurred when the following 2 conditions were both met: (1) 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and (2) 705 deaths were observed in all randomized participants. Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)
Secondary Median Number of Months With Progression Free Survival (PFS) Per mWHO in Participants Who Have Received at Least One Dose of Blinded Study Therapy at Primary Endpoint Progression-free survival (PFS) is defined as the time between the date of randomization and the date of tumor progression per Modified World Health Organization (mWHO) criteria or death, whichever occurs first. A participant who died without reported progression per mWHO criteria were considered to have progressed on the date of death. For participants who remain alive and have not progressed, PFS was censored on the date of last evaluable tumor assessment. For participants who remain alive and have no recorded post-baseline tumor assessment, PFS was censored on the day of randomization. Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)